Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | GALR3 | O60755 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248665 | 0.87 | SOAT1 (0.39) | ALDH1A1TSHRHSD17B10LMNATDP1 | |
| SCHEMBL614185 | 0.87 | SOAT1 (0.39) | ALDH1A1TSHRHSD17B10LMNATDP1 | |
| SCHEMBL2821617 | 0.81 | ALDH1A1 (0.39) | ALDH1A1TSHRHSD17B10LMNATDP1 | |
| SCHEMBL28886285 | 0.81 | HSD17B10 (0.44) | ALDH1A1TSHRHSD17B10LMNATDP1 | |
| SCHEMBL11792511 | 0.80 | NAAA (0.37) | ALDH1A1TSHRHSD17B10LMNATDP1 | |
| SCHEMBL13955258 | 0.80 | SOAT1 (0.35) | ALDH1A1TSHRHSD17B10LMNATDP1 | |
| SCHEMBL19821804 | 0.78 | SOAT1 (0.39) | ALDH1A1TSHRHSD17B10LMNASOAT1 | |
| SCHEMBL9060131 | 0.78 | TSHR (0.41) | ALDH1A1TSHRHSD17B10LMNATDP1 | |
| SCHEMBL11746994 | 0.78 | ALDH1A1 (0.40) | ALDH1A1TSHRHSD17B10LMNACHRM2 | |
| SCHEMBL1897727 | 0.78 | ALOX15 (0.33) | ALDH1A1HSD17B10SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002506-A1 | IMPROVED PROCESS FOR THE PREPARATION OF LURBINECTEDIN AND ITS MORPHS THEREOF | RK PHARMA INC. (US) | 2025-01-02 | — | — | US | claimed |
| CN-116235996-A | Electronic cigarette liquid and atomization device comprising same | 深圳雾芯科技有限公司 | 2023-06-09 | — | — | CN | claimed |
| WO-2023084329-A1 | IMPROVED PROCESS FOR THE PREPARATION OF LURBINECTEDIN AND ITS MORPHS THEREOF | RK PHARMA INC. (US) | 2023-05-19 | — | — | WO | claimed |
| CN-110089717-A | A kind of milk type essence containing to green pepper butyl methyl phenylacetate | 苏州禾田香料有限公司 | 2019-08-06 | — | — | CN | claimed |
| CN-110050982-A | A kind of green apple type edible essence containing the third two acetal of trans- 2- hexenoic aldehyde | 苏州禾田香料有限公司 | 2019-07-26 | — | — | CN | claimed |
| CN-106188040-B | A kind of Fevipiprant and its intermediate preparation method | 浙江宏鑫染化材料有限公司 | 2018-03-23 | — | — | CN | claimed |
| CN-107245065-A | A kind of method that catalytic hydrogenation ethyl levulinate prepares valerolactone | 贵州大学 | 2017-10-13 | — | — | CN | claimed |
| CN-104957585-B | A kind of cold drink Hami melon essence and preparation method thereof and its application | 天宁香料（江苏）有限公司 | 2017-03-15 | — | — | CN | claimed |
| CN-106188040-A | A kind of Fevipiprant and the preparation method of intermediate thereof | 浙江宏鑫染化材料有限公司 | 2016-12-07 | — | — | CN | claimed |
| CN-102030626-B | Method for preparing 5-methyl-2-hepten-4-one | SHANGHAI INST TECHNOLOGY | 2013-02-20 | — | — | CN | claimed |
| CN-102030626-A | Method for preparing 5-methyl-2-hepten-4-one | SHANGHAI INST TECHNOLOGY | 2011-04-27 | — | — | CN | claimed |
| CN-119285453-A | Preparation method of spice 5-methyl-2-hepten-4-one | 滕州鑫和生物科技有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20250002506-A1 | IMPROVED PROCESS FOR THE PREPARATION OF LURBINECTEDIN AND ITS MORPHS THEREOF | RK PHARMA INC. (US) | 2025-01-02 | — | — | US | disclosed |
| WO-2023084329-A1 | IMPROVED PROCESS FOR THE PREPARATION OF LURBINECTEDIN AND ITS MORPHS THEREOF | RK PHARMA INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-10640490-B2 | Diaminopyrimidine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2020-05-05 | — | — | US | disclosed |
| US-5002951-A | 2-amino-5-halo-4-pyrimidinol for bactericides and antiprotozoa agent | THE UPJOHN COMPANY (US) | 1991-03-26 | — | — | US | disclosed |
| US-4665077-A | IMMUNOREGULATORY AGENTS | THE UPJOHN COMPANY (US) | 1987-05-12 | — | — | US | disclosed |
| US-4619933-A | 6-aryl pyrimidines for treating aplastic anemia | THE UPJOHN COMPANY (US) | 1986-10-28 | — | — | US | disclosed |
| US-4543248-A | Method for immunoregulation with 6-aryl pyrimidine compounds | THE UPJOHN COMPANY (US) | 1985-09-24 | — | — | US | disclosed |
| US-4507302-A | Method for treating arthritis with 6-aryl pyrimidine compounds | THE UPJOHN COMPANY (US) | 1985-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002506-A1 | IMPROVED PROCESS FOR THE PREPARATION OF LURBINECTEDIN AND ITS MORPHS THEREOF | RXFP1, REN, CIAPIN1 | ALDH1A1 1940/4885TSHR 3288/4885HSD17B10 4158/4885 |
| US-10640490-B2 | Diaminopyrimidine derivatives and processes for the preparation thereof | HRH2, GIPR, SSTR4 | ALDH1A1 3199/4885TSHR 708/4885HSD17B10 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.